Two drugs of GSK Pharmaceuticals Taiwan Branch won the National Quality Award, and the general manager Yu Huiming received the certificates on behalf of the general manager.

On February 14, 2023, the 25th SNQ National Quality Mark was awarded, and GlaxoSmithKline (GSK) Taiwan Branch won the certification for its respiratory drugs, fully demonstrating GSK's strict quality control of drugs and cross-border clinical verification of drugs Affirmed by the review, practice GSK's corporate culture - consider patients, be responsible for impact, and do the right thing.

The SNQ national quality label sponsored by the National Biotechnology and Medical Science and Technology Policy Research Center of the foundation invites domestic and foreign biotechnology and medical companies to apply; the review shows that GSK products are the first in Taiwan to treat chronic obstructive pulmonary disease (COPD) and asthma The three-in-one long-acting dry powder inhaler is used in a single device. The evaluation has practical benefits and meets the quality and safety standards. It is approved and approved.

Sherman Yu, general manager of GSK Taiwan, said, "GSK is very honored to be certified by the National Quality Mark. We will continue to introduce more world-class medicines to Taiwan, contribute to the health and well-being of the Taiwanese people, and work together to overcome diseases. "

According to the 110-year statistical data of the Ministry of Health and Welfare, chronic lower respiratory diseases are the eighth among the top ten causes of death in Taiwan, and the disease burden is heavy (Note 1).

As a leader in the field of respiratory therapy, GSK has continuously invested in the research and development of asthma and COPD drugs for 50 years. From the launch of the world's first inhaler (Note 2) in 1969, GSK has developed 6 kinds of respiratory drugs within 5 years, and has continued to innovate , through drugs and vaccines, provides a series of respiratory products from prevention to treatment, protects patients in an all-round way, and promises to let everyone breathe freely.

GSK's performance in corporate governance, social and environmental sustainability has been outstanding in the global pharmaceutical industry. It has been listed in the Dow Jones Sustainability Index (DJSI) for many years in a row. In 2021, it will even rank first in the pharmaceutical industry; in 2022, GSK will also S&P Global Sustainability Assessment (S&P Global Sustainability Assessment) won the second place; GSK also attaches great importance to the right to access medicines of people in economically disadvantaged countries. From 2015 to 2022, GSK has been in the Access to Medicines Index (Access to Medicines Index) for eight consecutive years Ranked first (Note 3).

In Taiwan, as a strong partner of public health, GSK will continue to invest in general medicine, specialty medicine, vaccines, HIV and other fields. Make a positive impact.

Note 1: Statistical results of causes of death in 110 years - Ministry of Health and Welfare (mohw.gov.tw)

Note 2: History and heritage｜GSK

Note 3: 2022-esg-updates-at-a-glance.pdf (gsk.com) Page 4

(album)